Dana-Farber using new grant to study less-is-more approach to breast cancer
For years, oncologists have aggressively treated an early form of non-invasive breast cancer with surgery and radiation, carving out any part of the breast that was deemed to be a future risk.
But with a $13.3 million grant from the Patient-Centered Outcomes Research Institute, Dana-Farber Cancer Institute will study whether such aggressive treatments are necessary for ductal carcinoma in situ (DCIS), and if a wait-and-see approach leads to better outcomes for the patient.
Approximately 60,000…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Jessica Bartlett Source Type: news
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Grants | Health | Health Management | Pharmaceuticals | Study